This is a past event. Registration is closed. View other Viva Biotech Holdings events.
Cheney Mao
Chairman & CEO of Viva BiotechSelected to participate in the “The Thousand Talents Plan” initiated by Shanghai government in August 2012 and the PRC central government in March 2013
Ph.D. in Biochemistry from Cornell University
Post-doc research from Duke Medical Center
Former Director of the Department of Structural Biology of the Parker Hughes Institute
Yi Jing Xie
Managing Director of Healthcare & Life SciencesXie Yi Jing co-founded China Renaissance. He is a Managing Director and head of the healthcare advisory team overseeing the financial advisory business for the healthcare sector. Since joining China Renaissance, Mr. Xie has held various management positions, including managing director of the financial sponsor team. Mr. Xie previously worked at Credit Suisse and served as vice president within its investment banking division.
Mr. Xie holds a bachelor’s degree in economics from the University of Sydney.
Rachel Yu
Managing Director of 华兴资本Rachel is Managing Director in China Renaissance healthcare and life sciences team; Since joining in CR in 2015, She is responsible for industry and client coverage in Life Science sector and has successfully completed near 30 private financing placement transactions, with total financial amount more than $2bn. Prior to joining CR, Rachel heldd equity analyst position at Deutsche Bank at New York focused on US healthcare equity research; Before that, Rachel worked at Genentech R&D for five years as research associate. Rachel hold an MBA degree from University of Chicago Booth School of Business, and MS in Molecular Pharmacology from University of Missouri - Columbia.
Jonathan Zhu
Managing Director of Bain Capital Private EquityMr. Zhu received a JD from Cornell Law School, an MA from Nanjing University, and a BA from Zhengzhou University in China.
Mr. Zhu joined Bain Capital Private Equity in 2006. He has led many of our investments in China and is currently focused on the Financial and Business Services and Healthcare verticals. Mr. Zhu is Co-head of Asia Private Equity.
Prior to joining Bain Capital Private Equity, was an investment banker at Morgan Stanley and CEO of its China business sector.
陈鹏辉
创始人 at 博远资本陈鹏辉（Kevin Chen），博远资本创始合伙人，专注于医疗大健康领域，在跨国医疗企业和医药投资领域有20逾年的工作经历，具有深厚的海内外行业人脉，又兼有国际化背景。主导及参与投资了华大基因、贝达药业、美中宜和、合全药业、鱼跃医疗、启明瓣膜、挂号网、再鼎医药等多个知名案例。此前是红杉资本中国基金合伙人，负责医疗健康行业投资，并且是美敦力红杉医疗器械创新基金的创始成员和投委会成员。曾是光大控股医疗健康基金创始人和负责人。在此之前任尚华医药总裁、首席运营官及首席财务官。陈鹏辉先生拥有南京大学化学学士学位、杜兰大学药物化学硕士及美国西北大学凯洛格商学院（Kellogg)工商管理硕士学位。
Yi Dan Chen
Executive Partner at GIGGIG Executive Partner, Head of International BD.
Ph.D. in Pharmacology, School of Medicine, UC San Diego.
Dr. Chen has worked as a research scientist at Harvard Medical School, Technical Lead, CTO, and a senior consultant for the APAC headquarter of Agilent Technologies (Seahorse Bioscience), Director of Strategic Development of Beijing Promed, Cofounder of I&I Ventures (a global med-tech VC), etc. She has led M&A, IPO, fund-raising, and out-licensing of several companies as a member of the core management team or as a senior consultant.
She has extensive professional background and connections in healthcare industries, with expertise in VC investment and US-China strategic business development. She has been the board member of Chinese Entrepreneur Association since 2014, and the judge for MassChallenge, the famous global start-up competition in Boston, since 2017.
John Zhu
Partner at 6 Dimensions CapitalDr. John Zhu, Partner of 6Dimensions Capital. Prior to that, he worked for Wuxi Ventures, Greenwoods Asset, Applied Biosystems, etc. Dr. Zhu has over 15 years of experience in health care industry. He has led 20+ private equity investments, including CStone Pharma, Phoenix Healthcare Group, BGI, Gan&Lee, etc. He earned his MBA from University of California at Berkeley and PhD from University of Massachusetts Medical Center.
Dan Zhang
Executive Chairman at Fountain MedicalDr. Zhang was the Head of Clinical Development and was Safety Assessment at Sigma-Tau Research Inc-leading Italian Pharmaceutical Company, He was the vice president of Quintiles Transnational Corp., and Chairman of Quintiles Medical Development (Shanghai) Company Ltd.,
Dr. Zhang is a member of grant review committee for National Drug Development Fund of China, and is also a consultant for the China Food and Drug Administration. He is a member of ICH E19 Expert Working Group. He is also chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. Dr. Zhang is also a senior consultant for the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. Dr. Zhang was the board of directors for the Sino-American Pharmaceutical Association and was the former president of Chinese Biopharmaceutical Association-USA (CBA). Dr. Zhang is chairing the government relationship committee of Bayhelix.
Dr. Zhang received his pre-med training from Peking University and received M.D. from Peking Union Medical College. He then received MPH from the Harvard School of Public Health. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.
Wang Shen
Founder of VivaVision Biotech LimitedPh.D., University of Pittsburgh
Experience in Abbott, Kanion, Amgen, Sunesis
Yimin Zou
Founder of VersaPeutics, Inc.Postdoctoral Fellowship at University of California, San Francisco and San Diego
Ph.D. University of California, Davis and San Diego
~45 publications
Qun(Max) Dang
CEO of InnovStone CSPCMax received his Ph.D. in organic chemistry from Purdue University in 1992.
Max has extensive experiences in business development globally and more than 25-years of experiences as a manager of drug discovery programs spanning from early to late stages; led programs that advanced multiple compounds into human clinic trials ;experiences in therapeutic areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver fibrosis, anemia, viral and bacterial infections; extensive knowledge of SBDD, Medicinal Chemistry, Drug Delivery, Prodrugs, Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside Chemistry; more than 5 years of managing drug discovery programs executed at various CROs. He led to 91 publications and 60 patents.
Chen Chen
Founder of ABM Therapeutics, Inc.Postdoctoral Research Fellow, Texas A&M University
Experience in Sundia MediTech as CEO
Published over 110 research papers and Co-invented 24 US patents/patent applications
Shunqi Yan
COO & Founder of Arthrosi Therapeutics, Inc.Ph.D., Rutgers University
Experience in Schrodinger, Arquele, Valeant, IGNYTA
Key participant in 7 clinical drugs, including 2 first-in-class drugs
Harry Zhou
Founder of Proviva Therapeutics, Inc.Ph.D., New York University，Postdoc., Univ. of Pennsylvania
Over 22 years of experience in R&D of biotherapeutics in metabolic, autoimmune/inflammatory diseases and cancer at Schering AG, Immunex, Amgen, GSK, Fabion Pharmaceuticals, and EMD Serono.
Founder of Fabion Pharmaceutical (USA, 2011)
Founder of EB1 Biotech (Israel, 2018)
ZhiXiong Ye
CSO at Viva BiotechSelected to participate in the "The Thousand Talents Plan"
Ph.D. from University of Minnesota
Former Senior Research Fellow at Merck
15+ years of experience in drug discovery and clinical candidate development
David Xu
CBO at Viva BiotechPh.D. from University of California, Los Angeles
Postdoctoral research at the Scripps Research Institute
M.B.A from Wharton School of Business, University of Pennsylvania
Worked in Purdue, Sandoz, and Novartis
Yiwei Zong
Founder of Anji Pharmaceuticals lncDr. Zong is co-founder and chief operating officer of Anji Pharma. He is an experienced investor and entrepreneur in biotech. He received his Ph.D. in Biomedicine from University of Pennsylvania and is a Chartered Financial Analyst.
Jerry Shen
Chief Executive Officer at AceLink Therapeutics, Inc.Yuqiao (Jerry) Shen, Ph.D.
Chief Executive Officer; Co-founder
Dr. Shen brings more than 20 years of pharmaceutical experience with a focus on drug development for cancer, genetic diseases and rare diseases. Before founding AceLink in 2019, he was Executive Director at BioMarin Pharmaceutical, responsible for small molecule drug discovery and development. He joined BioMarin in 2010 when the company acquired LEAD Therapeutics, a small drug discovery company where he served as VP of Drug Discovery Biology. Prior to LEAD Therapeutics, he served as VP of R&D at Applied Biomics, a protein biomarker research and service company that he co-founded. Prior to that, he worked at Onyx Pharmaceuticals, where he served at positions with increasing responsibilities and helped development of oncolytic viruses and gene delivery viral vectors.
Dr. Shen holds B.S. in Physiology from Fudan University, PhD in Molecular Biology from State University of New York at Buffalo, and received post-doctoral training in Dr. Thomas Shenk’s lab at Princeton University. He has co-authored more than 35 peer-reviewed papers and is a co-inventor in more than 30 issued and pending patents. In 2018, Talazoparib, a cancer drug for which he spent many years of his career both at LEAD and at BioMarin, received marketing approval from FDA.
Hua Lin
Co-Founder of ForkheadbioCo-Founder, Chief Scientific Officer
Completed her Ph.D. at the University of Michigan and was a Postdoc and Assciate Research Scientist at Columbia University before she went on to work as a Senior Resarch Biologist at Merk then as a Team Leader/Principal Resarch Scientist at Eli Lilly.
Kamal Azzaoui
Founder of Saverna Therapeutics AGDr. Kamal Azzaoui received his PhD from the University of Orléans (France) followed by 2 postdocs at McGill University (Montréal) and Georgetown University (Washington DC). Dr. Azzaoui worked for 2 years for a flavor and fragrance mid-size company as a senior computational chemist (Givaudan, Zurich, CH), 2 years as a computational chemist for a biotech startup (Hamit-Darwin-Freesh, Ivins, UT, USA), and 15 years at Novartis as a laboratory head in charge of data analysis, data modeling and drug design using machine learning, cheminformatics and molecular modeling tools. He left Novartis in 2017 to co-found Saverna Therapeutics, and is graduating in November 2019 from the master for advanced science (MAS) program of the Swiss Institute for Translational and Entrepreneurial Medicine (sitem-insel) at the University of Bern. He has contributed to many drug discovery projects in term of data analysis, machine learning, medicinal chemistry and cheminformatics support. He has worked closely with Novartis scientists to develop software such as HTS explorer, a data analysis tool for chemists. He also pioneered in developing machine learning models for the prediction of adverse effects and safety of novel drugs. He was a partner in the European Innovative Medicine Initiative (IMI OpenPhact) consortium. That allows him to interact with highly skilled international scientists and developers from pharmaceutical industry and academia. He has contributed to numerous drug discovery projects by proposing molecules that became lead compounds (one of the proposed molecule series from fragments screening entered the first patient in 2017). Furthermore, based on historical data he identified biological targets and pathways involved in bioactivity during phenotypic screens. Dr. Azzaoui is consulting for Elsevier, Openphact and Axxelis. He received the Novartis Select price in 2007 for hit prioritization from high throughput screening and the Excellence Award price for hit-to-lead Novartis course in 2008.
Richard Austin
CEO of Reglagene Holding, Inc.Richard leads Reglagene’s business operations and fund-raising. Before founding Reglagene, he built a 23- year career in pharmaceutical R&D at GSK and Sanofi in which he served as a medicinal chemist, drug discovery project leader, analytical chemistry services manager, and research operations manager. Recognizing an affinity for the business side of the pharmaceutical industry, in 2010 Richard earned an MBA in Pharmaceutical Management from Drexel University in Philadelphia Pennsylvania. He soon transitioned into a managerial role at Sanofi’s Tucson, Arizona Research Center with responsibilities for operational and capital spending, procurement, equipment maintenance, and other business areas. Richard is a member of Tucson’s Desert Angels, one of the most active angel investment groups in the United States. While serving as a Commercialization Partner for the University of Arizona, Richard was introduced to quadruplex gene expression control. Seeing the potential in the technology, he co-founded Reglagene in November 2016. Richard earned a PhD in Organic Chemistry from the University of Texas in 1991 and completed post-doctoral studies in bioorganic chemistry at the University of California Berkeley in 1993.
Daniele Biasci
Vice President at Totient Inc.Daniele is a research scientist in cancer immunology and leads the human antibodies program at Totient Inc. His research interests focus on genes that drive intratumoral immune response.
During his scientific career, Daniele developed the first and only test to predict clinical outcome in Crohn's disease, currently commercialised by a spinoff of the University of Cambridge (Biasci et al. Gut 2019). He was also the first to show that genetic variants conferring susceptibility to Crohn's disease are completely different from the ones determining disease course, a major determinant of patient well being (Lee, Biasci et al. Nature Genetics, 2017). Daniele completed his PhD in the Faculty of Medicine, University of Cambridge (UK) and was a Research Associate in Cancer Research UK Cambridge Institute. He was awarded a prestigious Schlumberger Research Fellowship in Darwin College, Cambridge (2015-2018).
Guochun Li
Partner at YuanBio Venture CapitalGuochun Li Ph.D. is partner of the YuanBio Venture Capital located in Suzhou, China. He has over 20 years of experience in biologics discovery and investment, with strong experience in leading biologics projects from concept to clinical development. Previously Dr. Li was Chief Scientific Officer of the Gloria Pharmaceuticals company. He served as Research Investigator at the Genomics Institute of the Novartis Research Foundation in US. Dr. Li was graduated from the University of Missouri-Columbia and received postdoctoral training at the University of California, San Diego.
Zhiping Cui
Assistant President at FosunFrom 2001 to 2005, he served as Deputy Director of the International Business Department of Shanghai Pharmaceutical Co., Ltd., Assistant to the General Manager and General Manager and Deputy General Manager of the International Business Department.
From 2006 to 2014, Vice President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and General Manager of International Department, in charge of the company's overseas pharmaceutical companies M&A and overseas development strategic planning.
From 2014 to 2017, he served as Vice President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., General Manager of VC Investment Department, and was in charge of VC investment.
He also serves as Vice Chairman of InnoStar Capital, Director of Amerigen Pharmaceuticals, Ltd., and Chairman of Tongde Equity Investment Management (Shanghai) Co., Ltd.
He holds a Bachelor of Pharmacy from Shanghai Medical University and gained an MBA from La Trobe University in Australia.
Shixiong Gan
Co-Founder of WisdomontPreviously as Managing Partner/CEO of Gopher Asset Management，Chief Risk Officer of Wanjia Asset Management，General Manager of Investment Banking in Tiantong Securities，Deputy General Manager of Shandong Jintai Co. Ltd, Research Engineer of China National Heavy Duty Truck Group Co. Ltd
26 years of senior management experience in securities, funds and asset management companies; lead the IPO and M&A of more than 80 companies including Suning, SD Gold, SINOTRUCK etc.; successful investment portfolios including Suntech(STP), Yingli(YGE), Concord Medical(CCM),Viva Biotech(01873) etc.; more than 10 years of experience in auto and medical industry; one of the few early participants in stock reform in China.
Education background: Master of Engineering Administration from Tianjin University; Bachelor of Science in Automobile Engineering from Chongqing University